Is GLP-1 Covered by Medicare?

Introduction

Medicare coverage for GLP-1 medications depends entirely on why you’re taking them. If you have type 2 diabetes, Medicare Part D plans typically cover Ozempic®, Mounjaro®, Trulicity®, and oral Rybelsus®. If you’re taking Wegovy® or Zepbound® purely for obesity, Medicare almost certainly will not pay.

That changed slightly in March 2024 when CMS allowed Part D plans to cover Wegovy for patients with established cardiovascular disease, after the SELECT trial (Lincoff et al. 2023 NEJM) showed a 20% reduction in major adverse cardiac events. Coverage for obesity alone remains banned under a 2003 statute, which is why bipartisan bills like the Treat and Reduce Obesity Act keep getting reintroduced.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

Which GLP-1 Drugs Does Medicare Cover Today?

Medicare Part D covers Ozempic, Mounjaro, Trulicity, Victoza®, Bydureon, and Rybelsus when prescribed for type 2 diabetes. Each plan sets its own formulary, so the specific drug and tier vary by insurer.

Quick Answer: Medicare Part D covers semaglutide and tirzepatide for type 2 diabetes

Wegovy received expanded Part D coverage in March 2024 after CMS issued guidance permitting plans to cover it for patients with established cardiovascular disease and overweight or obesity. The basis was SELECT, which enrolled 17,604 patients and showed a hazard ratio of 0.80 for cardiovascular death, nonfatal MI, or nonfatal stroke.

Zepbound got a similar pathway in late 2024 after SURMOUNT-OSA results led to FDA approval for moderate-to-severe obstructive sleep apnea. Patients with documented OSA plus obesity can request coverage, though plan response varies.

Why Won’t Medicare Pay for Weight Loss Drugs?

The Medicare Modernization Act of 2003 specifically excluded “agents used for anorexia, weight loss, or weight gain” from Part D coverage. That language was written when weight loss drugs meant phentermine and fen-phen, long before GLP-1s reshaped the field.

Repealing the exclusion has been proposed for over a decade. The Congressional Budget Office published a March 2024 analysis estimating that covering anti-obesity medications for all eligible Medicare beneficiaries would cost about $35 billion over a decade, though savings from prevented heart attacks, strokes, and joint replacements would offset some of that.

The Treat and Reduce Obesity Act (TROA), reintroduced in 2025, would allow Part D coverage. It has bipartisan sponsors but has stalled repeatedly over cost concerns.

How Does the Cardiovascular Disease Pathway Actually Work?

Your prescriber documents a qualifying cardiovascular event or established CVD, then prescribes Wegovy under the cardiovascular risk reduction indication, not weight loss. Qualifying conditions include prior heart attack, prior stroke, peripheral artery disease, or coronary artery disease.

The plan still requires prior authorization. About 30 to 40% of initial requests get denied for incomplete documentation, according to Kaiser Family Foundation tracking data from late 2024. A successful appeal usually adds 2 to 6 weeks.

Patients without prior cardiac events do not qualify, even if their 10-year cardiovascular risk is high. This frustrates clinicians who treat patients with diabetes, obesity, and elevated risk scores who haven’t yet had an event.

What Does GLP-1 Cost on Medicare Without Coverage?

Without coverage, list prices run roughly $1,000 to $1,350 per month for brand-name GLP-1 drugs. Ozempic lists around $968, Wegovy around $1,349, Mounjaro around $1,069, and Zepbound around $1,059 as of early 2026.

Manufacturer savings cards from Novo Nordisk and Eli Lilly exclude Medicare beneficiaries by federal law (the anti-kickback statute treats Medicare patients differently than commercially insured patients). That’s a frequent surprise. Patients who used a $25 copay card on commercial insurance often find no equivalent option after aging into Medicare.

Lilly’s direct-to-consumer Zepbound vials launched in 2024 at $399 to $699 for cash-pay, and Novo Nordisk added NovoCare for Wegovy at $499. These prices are available regardless of Medicare status because they don’t go through insurance.

Can Compounded Semaglutide Help Medicare Patients?

Compounded semaglutide is generally cash-pay through telehealth platforms and not billed to Medicare. Monthly costs run roughly $200 to $400 depending on dose and platform. TrimRx, for example, offers compounded semaglutide and tirzepatide through a free assessment quiz and personalized treatment plan.

The FDA’s shortage list for semaglutide ended in February 2025, which legally narrowed routine 503A compounding of identical-to-FDA formulations. Patient-specific compounded versions remain available when prescribed for documented clinical needs that the commercial product can’t meet, like specific dose adjustments or allergies to inactive ingredients.

This route has tradeoffs. Compounded products don’t undergo the same finished-drug review as brand versions, and Medicare won’t reimburse if there’s a side effect. Cost transparency is the main draw.

Key Takeaway: Medicare cannot legally cover weight loss drugs under current 2003 law

Does Medicare Advantage Cover Anything Original Medicare Doesn’t?

Medicare Advantage plans must cover everything Original Medicare covers but can add extras. A handful of MA plans have added limited obesity drug benefits as enhanced supplemental benefits, though most haven’t.

If you’re shopping plans during open enrollment, ask specifically about anti-obesity medication coverage and pull the formulary. Don’t rely on the broad marketing language about “wellness benefits.” Confirm the drug name, tier, prior auth requirements, and step therapy rules.

Some MA plans pair GLP-1 access with mandatory enrollment in lifestyle programs modeled after the Diabetes Prevention Program, which produced a 58% diabetes risk reduction in the major DPP trial.

What About Medicaid Coverage for GLP-1s?

State Medicaid programs can choose to cover anti-obesity medications. As of early 2026, about 15 states cover Wegovy or Zepbound for obesity, with the rest covering only diabetes indications. Coverage rules, prior authorization criteria, and BMI thresholds vary widely.

If you have dual eligibility (both Medicare and Medicaid), the state Medicaid program may pick up some costs Medicare doesn’t, but only in covered states. Check your state’s preferred drug list before assuming coverage.

How Can I Appeal a Medicare GLP-1 Denial?

You have five appeal levels under Part D. The first step is a redetermination by your plan within 7 days of denial. Submit additional clinical documentation, including A1C values, prior medication trials, cardiovascular history, and BMI.

If the redetermination fails, you can request reconsideration by an Independent Review Entity within 60 days. Patient advocacy groups including the Obesity Action Coalition publish appeal templates. Approval rates at the IRE level run around 25 to 35% for GLP-1 denials based on incomplete documentation.

Get your prescriber’s office involved early. Documentation quality drives the outcome more than persistence.

Bottom line: About 7% of Medicare beneficiaries with obesity have access through CVD pathway

FAQ

Does Medicare Cover Ozempic for Prediabetes?

No. Medicare Part D covers Ozempic only for type 2 diabetes diagnosed with an A1C of 6.5% or higher or other confirmed diagnostic criteria. Prediabetes (A1C 5.7 to 6.4%) does not qualify under current rules, even though prevention would arguably reduce long-term costs.

Will Medicare Cover Wegovy If I Had a Heart Attack 10 Years Ago?

Yes, if your prescriber documents the prior MI as established cardiovascular disease. There’s no time limit on when the event occurred. You’ll still need a BMI of 27 or higher and prior authorization approval.

Can I Use GoodRx with Medicare?

Yes, but you can’t combine GoodRx with Medicare Part D for the same fill. You choose one or the other at the pharmacy. For some drugs, GoodRx beats your plan’s copay, especially before you hit the deductible. Compare both before paying.

Does Medicare Cover Tirzepatide for Sleep Apnea?

Coverage is plan-dependent and inconsistent. Zepbound was FDA-approved for moderate-to-severe OSA in December 2024 based on SURMOUNT-OSA. Some Part D plans added coverage in 2025, others haven’t. You’ll need a documented OSA diagnosis from a sleep study.

What’s the Cheapest Way to Get GLP-1 on Medicare?

If you have type 2 diabetes, your Part D plan probably covers Ozempic or Mounjaro at a tier 3 copay. If you don’t, your options are paying retail with manufacturer direct-to-consumer programs (Wegovy NovoCare at $499 or Zepbound vials at $399 to $699), or going outside Medicare for compounded semaglutide through telehealth platforms.

Is There Any Medicare Obesity Benefit at All?

Yes. Medicare Part B covers intensive behavioral therapy for obesity through a primary care provider, including weight loss counseling visits. Medicare also covers bariatric surgery for patients with BMI 35 or higher with comorbidities. Drug coverage is the gap.

Will the Medicare GLP-1 Rules Change in 2026 or 2027?

Possibly. The TROA bill remains active, and CMS has signaled openness to expanding indication-based coverage as more outcome trials read out. FLOW (Perkovic et al. 2024 NEJM) showed a 24% reduction in kidney failure and cardiovascular death with semaglutide in CKD patients, which could anchor another coverage pathway. Nothing is final.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.